TerminatedNot Applicable

Efficacy Study of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Pneumonia

Taiwan49 participantsStarted 2013-10-01

Plain-language summary

There might be additional benefit on clinical outcomes from adjunctive colistimethate sodium inhalation as therapy for multidrug resistant Gram-negative ventilator-associated pneumonia.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. age ≥ 20 years old
✓. medical ICU patients with invasive ventilator use ≥ 48 hours
✓. multidrug resistant Gram-negative bacteria obtained from lower respiratory tract

Exclusion criteria

✕. pregnancy
✕. concurrent use of other antimicrobial agents active for isolated multidrug resistant Gram-negative bacteria (as defined as resistant to carbapenem, fluoroquinolone, and anti-pseudomonas beta-lactams), such as tigecycline, aminoglycosides, and sulbactam
✕. patients who refuse to receive any inhaled therapy

What they're measuring

clinical cure rate

Timeframe: From date of starting colistimethate sodium to 28th days or til discharge from hospital, whichever came first, assessed up to 28 days

Trial details

NCT IDNCT01975350

SponsorNational Taiwan University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-02-04

View on ClinicalTrials.gov More Ventilator Associated Pneumonia trials